29 June 2020
: Case report 
Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Patient complains / malpractice, Rare disease
Masafumi SekiACDEFG, Yasuhiro KamiokaBC, Kazuki TakanoBCD, Haruka ImaiBC, Mai ShojiBC, Maya HariuBCD, Yukari KabutoyaB, Yuji WatanabeABCDDOI: 10.12659/AJCR.924642
Am J Case Rep 2020; 21:e924642
Table 1. Drug susceptibilities of Mycobacterium abscessus isolated from peritoneal fluid.
| No. | Drugs | MIC | S/I/R |
|---|---|---|---|
| 1 | SM | 32 | R |
| 2 | EB | 32 | R |
| 3 | KM | 16 | R |
| 4 | RIP | >32 | R |
| 5 | LVFX | 2 | I |
| 6 | CAM | 0.125 | S |
| 7 | TH | >16 | R |
| 8 | AMK | 16 | R |
| 9 | IPM/CS | >32 | |
| 10 | MINO | >256 | |
| 11 | DAP | >256 | |
| 12 | LZD | >256 | |
| MIC – minimal inhibitory concentrations; S – susceptible; I – intermediate; R – resistance; SM – streptomycin; EB – ethambutol; KM – kanamycin; RIP – rifampicin; LVFX – levofloxacin; CAM – clarithromycin; TH – ethionamide; AMK – amikacin; IPM/CS – imipenem/cilastatin; MINO – minocycline; DAP – daptomycin; LZD – linezolid. | |||